Location History:
- Copenhagen, DK (2006)
- Hørsholm, DK (2010)
- Hoersholm, DK (2011 - 2013)
Company Filing History:
3 out of 24 
2 out of 8 
1 out of 8 Years Active: 2006-2013
Title: Innovations of Lucilla Steinaa in Cancer Therapy
Introduction
Lucilla Steinaa, an accomplished inventor based in Hørsholm, Denmark, has made significant contributions in the field of biomedicine, specifically in cancer therapy. With a remarkable portfolio of six patents, her work focuses on the development of recombinant antibodies designed to target and combat human cancers.
Latest Patents
One of her notable inventions is the "Recombinant anti-epidermal growth factor receptor antibody compositions." This invention pertains to the use of recombinant antibodies for human cancer therapy, specifically targeting the human epidermal growth factor receptor (EGFR). The compositions described in the patent exhibit impressive synergy, particularly with mixtures containing three or more antibodies, in reducing the proliferation of various cancer cell lines. Additionally, her work demonstrates promising results with compositions that include two distinct chimeric anti-hEGFR antibodies, revealing a novel mechanism of action through the rapid and efficient internalization of the receptor, which leads to terminal differentiation and tumor eradication in animal models. Remarkably, these antibodies can be produced in a single bioreactor as polyclonal antibodies, streamlining the manufacturing process.
Career Highlights
Lucilla Steinaa has built an impressive career in the biotechnology sector, contributing her expertise to influential companies such as Symphogen A/S and Bn Immunotherapeutics, Inc. Her innovative spirit and dedication to advancing cancer therapy reflect her pivotal role in modern medical research.
Collaborations
Throughout her career, Lucilla has collaborated with notable colleagues, including Allan Jensen and Søren Mouritsen. These partnerships have undoubtedly enriched her research and fostered an environment conducive to groundbreaking discoveries in antibody therapies.
Conclusion
Lucilla Steinaa represents a transformative figure in the realm of cancer treatment innovations. Her expertise in developing recombinant antibody compositions opens up new avenues for human therapy, showcasing the intersection of science and compassion. As her work continues to evolve, it holds immense potential for benefiting patients and advancing the field of cancer therapeutics.